Blockchain Registration Transaction Record

Soligenix Advances Novel Light Therapy for Hard-to-Diagnose Skin Cancer

Soligenix develops HyBryte™, a novel visible light therapy for early-stage cutaneous T-cell lymphoma (CTCL) that targets cancer cells while minimizing damage to healthy tissue.

This development matters because CTCL is notoriously difficult to diagnose in early stages, often leading to delayed treatment and poorer outcomes. Current ultraviolet-based phototherapies carry significant long-term safety risks, including skin damage and increased cancer risk with cumulative exposure. HyBryte's visible light activation offers a potentially safer alternative that targets malignant cells while sparing healthy tissue, which could transform early-stage CTCL treatment. For patients facing this rare cancer, this represents hope for more effective management with fewer side effects. Additionally, as a rare disease therapy, successful development could establish a new standard of care and potentially expand to other conditions like psoriasis, benefiting broader patient populations.